Nicolas Magné

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

J. Blay, B. Bui, J. Soria, 2009, European journal of cancer.

Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression.

N. Magné, F. Lévi, G. Milano, 2003, European journal of cancer.

Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients.

N. Magné, G. Poissonnet, O. Dassonville, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy.

N. Magné, G. Poissonnet, O. Dassonville, 2001, European journal of cancer.

Pharmacological background of EGFR targeting.

N. Magné, G. Milano, M. Etienne-Grimaldi, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil

N. Magné, A. Dubreuil, J. Formento, 2003, British Journal of Cancer.

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)

G Milano, N. Magné, P. Laurent-Puig, 2002, British Journal of Cancer.